中国临床药理学杂志2017，Vol.33Issue(3)：235-238,4.DOI:10.13699/j.cnki.1001-6821.2017.03.013
注射用血栓通对血脑屏障的通透性研究
Study of Xueshuantong injection on permeability of the blood brain barrier
摘要
Abstract
Objective To study the permeability of the main active ingredients of Xueshuantong Injection(Lyophilized powder),such as Ginsenoside Rb1,Ginsenoside Rd,Ginsenoside Re,Ginsenoside Rg1 and Notoginsenoside R1 by establishing the blood brain barrier (BBB) in vitro.Methods The bEnd.3 was used to establish the BBB in vitro,which consisted of normal group and model group.Mter normal culture 6 h in normal group and oxygen glucose deprivation (OGD) 6 h in model group,these groups were given 50 μg · mL-1 Xueshuantong Injection 0.2 mL to culture 4 h.The Pappof the main active ingredients in each group were measured by using a liquid chromatography tandem mass spectrometry(LC-MS/MS).Results The Papp of the Ginsenoside Rb1,Ginsenoside Rd,Ginsenoside Re,Ginsenoside Rg1 and Notoginsenoside R1 in normal group were (70.37 ± 5.78) × 10-s,(102.36 ± 69.21) × 10-9,(0.57 ±0.38) × 10-9,(98.96 ± 15.52) × 10-9,(382.18 ±42.49) × 10-9 cm · s The Papp of the Ginsenoside Rb1,Ginsenoside Rd,Ginsenoside Re,Ginsenoside Rg1 and Notoginsenoside R1 in model group were (116.20±21.80) × 10-s,(555.40 ±202.65) × 10-9,(2.96 ± 1.43) ×10-9,(202.66 ± 37.5) × 10-9,(634.26 ± 124.40) × 10-9 cm · s-1 The Papp of the model group was significant higher than that of normal group (P ＜ 0.05).Conclusion Mter bEnd.30GD 6 h,the BBB opens,and Xueshuantong Injection (Lyophilized powder) can exert neuroprotective effects across the blood brain barrier.关键词
注射用血栓通(冻干)/缺氧/血脑屏障/跨内皮电阻Key words
Xueshuantong Injection (Lyophilized powder)/oxygen glucose deprivation/blood brain barrier/trans endothelial electrical resistance分类
医药卫生引用本文复制引用
赵莼,郭虹,徐杨杨,王少峡,柴丽娟,袁庆,胡利民..注射用血栓通对血脑屏障的通透性研究[J].中国临床药理学杂志,2017,33(3):235-238,4.基金项目
国家重大新药创制基金资助项目(2012ZX09101201) （2012ZX09101201）
国家自然科学基金资助项目(8157140605) （8157140605）
天津市应用基础与前沿技术研究计划基金资助项目(14JCYBJC28900) （14JCYBJC28900）
广西科学研究与技术开发计划基金资助项目(14125008-2-5) （14125008-2-5）
